Please login to the form below

Not currently logged in
Email:
Password:

Cytokinetics

This page shows the latest Cytokinetics news and features for those working in and with pharma, biotech and healthcare.

Amgen, Cytokinetics’ heart failure drug disappoints in phase 3

Amgen, Cytokinetics’ heart failure drug disappoints in phase 3

Following the publication of the results, shares in Amgen dropped down by 4.6%, with shares in California-based Cytokinetics falling by 43%. ... Omecamtiv mecarbil, originally developed by Cytokinetics, is designed to increase the duration of cardiac

Latest news

More from news
Approximately 5 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Sale of Priority Review Voucher (PRV). 125. Cytokinetics/ Royalty Pharma. 4.5% royalty on global sales of omecamtiv mecarbil for heart failure (phase III).

  • Deal Watch July 2016 Deal Watch July 2016

    Real Relationships. Astellas and Cytokinetics have announced another extension to their agreement involving the development of their skeletal muscle activators, tirasemtiv and CK-2127107. ... 181. Cytokinetics/ Astellas. Tirasemtiv, CK-2127107 and

  • Astellas: Ten years young Astellas: Ten years young

    option, while in muscle disease Astellas is working with Californian clinical-stage biopharmaceutical company Cytokinetics, looking at mechanisms for improving muscle strength.

  • Heart failure therapy embarks on a new era Heart failure therapy embarks on a new era

    In collaboration with Cytokinetics, Amgen is developing omecamtiv mecarbil, an activator of cardiac myosin that is designed to increase the duration of cardiac muscle contractility and improve cardiac muscle performance.

  • Deal Watch table for December 2014 Deal Watch table for December 2014

    Licence. 700. Cytokinetics / Astellas Pharma. CK-2127107, fast skeletal troponin activator, in Spinal Muscular Atrophy and other neuromuscular indications (p1).

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
The Good Ideas Group

Remarkable but responsible creative work. We're most passionate about the pursuit of original, powerful ideas that our clients can harness...

Latest intelligence

What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...